Guttmann R D
Transplant Proc. 1977 Mar;9(1):755-60.
A hyperimmune antiserum from WfBN F1 hybrid rats primed to hyperacutely reject LBN F1 cardiac allografts has been studied. A large volume of antiserum will cause allograft rejection in less than 1 day. In the in vitro MLI, concentrations of this antiserum as low as 0.05% are markedly suppressive. This suppression is dose-dependent and immunizing-strain-specific at concentrations less than 1%. The suppressive activity is in the globulin fraction. After in vivo absorption, donor-strain specificity is clearly shown, with some cross-reactivity with third-party ACI strain. Moderate suppression of the rat MLI was seen with some normal rat sera, and augmentation of the MLI was seen in some experiments when very dilute concentrations of hyperimmune serum were used. Since suppression or augmentation of the MLI can occur as a function of antiserum dose and presumably antibody concentration, single measurements of MLI blocking factors may be misleading, and MLI suppression is not necessarily a correlate of allograft enhancement.
对一只经超急性排斥LBN F1心脏同种异体移植物致敏的WfBN F1杂种大鼠的超免疫抗血清进行了研究。大量抗血清会在不到1天的时间内导致同种异体移植物排斥。在体外混合淋巴细胞反应(MLI)中,低至0.05%浓度的这种抗血清具有明显的抑制作用。这种抑制作用呈剂量依赖性,且在浓度低于1%时具有免疫品系特异性。抑制活性存在于球蛋白部分。体内吸收后,明显表现出供体品系特异性,与第三方ACI品系有一些交叉反应。一些正常大鼠血清对大鼠MLI有中度抑制作用,在一些实验中,当使用非常稀释浓度的超免疫血清时,MLI会增强。由于MLI的抑制或增强可能是抗血清剂量以及推测的抗体浓度的函数,因此对MLI阻断因子的单次测量可能会产生误导,并且MLI抑制不一定与同种异体移植物增强相关。